New study aims to unlock XLH mysteries in adults
NCT ID NCT07607600
First seen May 26, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This study will follow 100 adults with X-linked hypophosphatemia (XLH) who are already taking burosumab. Researchers want to see how phosphate levels change over time and how they relate to bone health and overall disease burden. The goal is to better understand the condition and improve future management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED HYPOPHOSPHATEMIA (XLH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliera di Padova - U.O.C. di Gastroenterologia
Padova, 35128, Italy
-
Bone Research and Education Centre
Oakville, Ontario, L6M 1M1, Canada
-
CHU de Bicetre
Le Kremlin, 94275, France
-
Charite Campus Virchow
Berlin, 13353, Germany
-
Endokrinologikum Goettingen
Göttingen, 37075, Germany
-
Fondazione Policlinico Universitario Campus Bio-Medico
Rome, 00128, Italy
-
Fukuoka University - Fukuoka University Hospital
Fukuoka, Fukuoka, 814-0180, Japan
-
Hopital Cochin - APHP
Paris, 75014, France
-
Indiana University Hospital
Indianapolis, Indiana, 46202-5271, United States
-
Iseikai International General Hospital
Osaka, 530-0052, Japan
-
Istituto Auxologico Italiano
Milan, 20145, Italy
-
Japan Community Healthcare Organization Osaka Hospital
Osaka, 553-0003, Japan
-
Leiden University Medical Center (Leids Universitair Medisch Centrum (LUMC))
Leiden, 2333 ZA, Netherlands
-
Monash University - Monash Medical Centre (MMC)
Clayton, Victoria, 3168, Australia
-
Northern Sydney Cancer Centre-Royal North Shore Hospital (RNSH)
St Leonards, New South Wales, 2065, Australia
-
Office of Francesco Di Costanzo, MD
Sesto Fiorentino, Florence, 50019, Italy
-
Okayama Saiseikai Outpatient Center Hospital
Okayama, Okayama-ken, 700-0013, Japan
-
The Ohio State University Wexner Medical Center (OSUWMC) - CarePoint East
Columbus, Ohio, 43203, United States
-
The University of Tokyo Hospital
Bunkyo-ku, Tokyo, 113-8655, Japan
-
Universitat Wurzburg Koenig-Ludwig-Haus
Wuezburg, 97074, Germany
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-8148, United States
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
-
Yale University School of Medicine
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could provide clearer guidance on managing XLH with burosumab, potentially improving bone health and quality of life for patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.